Search results: (10000)
News Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis published last year assessed its efficacy and safety in patients previously treated for hemophilia A.
News Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the work presented below discuss the significance of prophylactic administration of factor VIII coagulation concentrates, specifically concerning neurological complications related to bleeding.
News Interactive Case Study: AATD – Alpha-1-Antitrypsin Deficiency
We present a case study of a man who was 41 years old at the time of his first contact with a pulmonary doctor. He came with symptoms of allergic seasonal rhinoconjunctivitis, proven sensitivity to spring trees, grasses, and dust mites, otherwise healthy, a parrot breeder. He is a former smoker with a smoking history of 20 pack-years. He was examined for exertional dyspnea, cough, recurrent respiratory infections, and wheezing. Try to follow the further diagnostic procedure and considerations with us, where you can choose between different options. At the same time, you will verify whether you proceeded correctly, along with the justification for the step taken.
News Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients with non-small cell lung cancer (NSCLC) with a mutation in the ROS1 gene.
News Safety of Long-Term Therapy with Bevacizumab in Oncological Patients
The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study published in the journal The Oncologist deals specifically with its long-term safety and tolerability in patients with various types of solid tumors.
News Effectiveness of Idarucizumab Reversal Effect
It is, of course, a great advantage if doctors have a specific substance available that counteracts the effect of oral anticoagulants in urgent need. Idarucizumab is a humanized monoclonal antibody that binds dabigatran with high affinity. The drug was approved for clinical use based on an interim analysis of the results of 90 patients enrolled in the RE-VERSE AD study. What conclusions were drawn based on the results of the entire study population?
News Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation
A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its type. This allowed for a comparison between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).
News Current Insights into the Etiology of Community Pneumonia: Pneumococci Still Leading?
The etiology of community-acquired pneumonias has undergone certain changes since the beginning of the antibiotic era. According to current guidelines, it is still recommended to initiate empirical antibiotic therapy upon diagnosing community-acquired pneumonia. However, there are certain concerns associated with the recommendation of empirical antibiotic therapy, especially regarding the increasing occurrence of bacterial antibiotic resistance. The aim of the study presented below was to specify the most frequently isolated pathogens of community-acquired pneumonia between 1945 and 2020.
News Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data from over 10 years of follow-up in patients with both radiographic and non-radiographic forms of axSpA were recently published in the journal Therapeutic Advances in Musculoskeletal Disease as part of the extended clinical trial ESTHER.
News Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing worldwide, and the combination of both diseases significantly worsens the prognosis of patients. One of the main causes of increased mortality in these patients is macrovascular complications of DM2. The burden on the cardiovascular system is even greater with the concurrent occurrence of chronic heart failure.
News New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis
Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a closer look at this recently approved drug in our brief summary.
News Efficacy of Sublingual Immunotherapy in Patients with Atopic Dermatitis Sensitized to Dust Mite Allergens
In patients with atopic dermatitis (AD), sensitization to house dust mite allergens is common. According to studies, subcutaneous immunotherapy (SCIT) represents an effective adjunct therapy. The clinical study presented below is one of the few that explored the efficacy of sublingual immunotherapy (SLIT) containing Dermatophagoides pteronyssinus extract.
News What Shape and Size of Tablets Do Our Patients Prefer?
The size and shape of tablets can affect patients' compliance with treatment. The following article provides an overview of conclusions from two foreign studies focused on influencing the difficulty of swallowing and handling tablets depending on their shape and size.
News How many heart failure patients do not take adequate doses of beta-blockers even though they could?
A British study published last year investigated the proportion of heart failure patients with reduced ejection fraction (HFrEF) who do not take an adequate dose of beta-blockers (BB), despite having no contraindications to their use. The authors analyzed the mortality of these patients over 7.6 years and looked for factors associated with the prescription of suboptimal BB doses.
News Impact of Combined Oral Contraceptives on Body Weight
A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and 2 mg chlormadinone acetate (CMA) for 6 months, comparing the results between the two groups.